BR112023026409A2 - Índices de diagnóstico para condições neurodegenerativas - Google Patents
Índices de diagnóstico para condições neurodegenerativasInfo
- Publication number
- BR112023026409A2 BR112023026409A2 BR112023026409A BR112023026409A BR112023026409A2 BR 112023026409 A2 BR112023026409 A2 BR 112023026409A2 BR 112023026409 A BR112023026409 A BR 112023026409A BR 112023026409 A BR112023026409 A BR 112023026409A BR 112023026409 A2 BR112023026409 A2 BR 112023026409A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnostic
- response
- neurodegenerative conditions
- diagnostic indices
- indices
- Prior art date
Links
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000001808 exosome Anatomy 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
índices de diagnóstico para condições neurodegenerativas. um método para avaliar indivíduos com certas doenças neurodegenerativas (por exemplo, doença de parkinson) em relação ao diagnóstico etiológico, prognóstico e resposta à terapia envolvendo a coleta não invasiva de uma amostra biológica (por exemplo, sangue venoso), isolamento de pequenas células extracelulares derivadas de neurônios vesículas (por exemplo, exossomos), ensaio de seu conteúdo externo e/ou interno para quantidades de biomarcadores informativos (por exemplo, quinases de sinalização, proteínas catalíticas e espécies de mirna) para a construção de algoritmos de diagnóstico/prognóstico/resposta de utilidade clínica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163210939P | 2021-06-15 | 2021-06-15 | |
| PCT/US2022/033517 WO2022266160A1 (en) | 2021-06-15 | 2022-06-15 | Diagnostic indices for neurodegenerative conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023026409A2 true BR112023026409A2 (pt) | 2024-03-05 |
Family
ID=84526684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023026409A BR112023026409A2 (pt) | 2021-06-15 | 2022-06-15 | Índices de diagnóstico para condições neurodegenerativas |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4356143A1 (pt) |
| JP (1) | JP2024526089A (pt) |
| KR (1) | KR20240023113A (pt) |
| CN (1) | CN117795343A (pt) |
| AU (1) | AU2022293855A1 (pt) |
| BR (1) | BR112023026409A2 (pt) |
| CA (1) | CA3222315A1 (pt) |
| IL (1) | IL309313A (pt) |
| MX (1) | MX2023014948A (pt) |
| TW (1) | TW202401009A (pt) |
| WO (1) | WO2022266160A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087978A1 (en) * | 2017-12-19 | 2019-06-27 | Chase Therapeutics Corporation | Methods for developing pharmaceuticals for treating neurodegenerative conditions |
| WO2021138364A1 (en) * | 2019-12-31 | 2021-07-08 | Chase Therapeutics Corporation | Kinases as biomarkers for neurodegenerative conditions |
-
2022
- 2022-06-15 MX MX2023014948A patent/MX2023014948A/es unknown
- 2022-06-15 IL IL309313A patent/IL309313A/en unknown
- 2022-06-15 CN CN202280054817.XA patent/CN117795343A/zh active Pending
- 2022-06-15 BR BR112023026409A patent/BR112023026409A2/pt unknown
- 2022-06-15 JP JP2023577307A patent/JP2024526089A/ja active Pending
- 2022-06-15 KR KR1020247001457A patent/KR20240023113A/ko unknown
- 2022-06-15 EP EP22825715.0A patent/EP4356143A1/en active Pending
- 2022-06-15 WO PCT/US2022/033517 patent/WO2022266160A1/en active Application Filing
- 2022-06-15 AU AU2022293855A patent/AU2022293855A1/en active Pending
- 2022-06-15 CA CA3222315A patent/CA3222315A1/en active Pending
- 2022-07-20 TW TW111127219A patent/TW202401009A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024526089A (ja) | 2024-07-17 |
| AU2022293855A1 (en) | 2024-01-18 |
| IL309313A (en) | 2024-02-01 |
| WO2022266160A1 (en) | 2022-12-22 |
| CA3222315A1 (en) | 2022-12-22 |
| KR20240023113A (ko) | 2024-02-20 |
| CN117795343A (zh) | 2024-03-29 |
| EP4356143A1 (en) | 2024-04-24 |
| MX2023014948A (es) | 2024-04-02 |
| TW202401009A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boulagnon et al. | Post-mortem biochemistry of vitreous humor and glucose metabolism: an update | |
| Kinn et al. | Age-dependent variation in cytokines, chemokines and biologic analytes rinsed from the surface of healthy human skin | |
| Donnino et al. | APACHE II scoring to predict outcome in post-cardiac arrest | |
| Murase et al. | The relation between breast milk sodium to potassium ratio and maternal report of a milk supply concern | |
| AR107561A2 (es) | Ensayo elisa para la detección de vegf | |
| Chornenki et al. | Identification of hemostatic markers that define the pre‐DIC state: A multi‐center observational study | |
| Batista Muñoz et al. | Role of beta-2-microglobulin as a biomarker in very preterm and extremely preterm infants with CNS inflammation | |
| Fyneface et al. | Assessment of Creatinine Levels in Blood and Saliva of Heamodialysed Subjects | |
| CN104862310A (zh) | 精神分裂症生物标记物、筛选方法及试剂盒 | |
| Garland et al. | The effects of different sampling techniques on peripheral post mortem tryptase levels: a recommended sampling method | |
| Gharib et al. | Chemokines in vitiligo pathogenesis: CXCL10 and 12 | |
| BR112023026409A2 (pt) | Índices de diagnóstico para condições neurodegenerativas | |
| CN105506074A (zh) | 一种用于精神分裂症诊断的lncRNA标志物及试剂盒 | |
| Kilonzo et al. | Renal dysfunction among adult patients in Mwanza, Tanzania: prevalence, outcomes and associated factors | |
| Pierce et al. | Development of a point-of-contact technique to measure adenosine triphosphate: A quality improvement study | |
| Prasad et al. | Childhood bacterial meningitis and usefulness of C-reactive protein | |
| Baisse et al. | Unexplained hypothermia is associated with bacterial infection in the emergency department | |
| Nitsch-Osuch et al. | Accuracy of rapid influenza detection test in diagnosis of influenza A and B viruses in children less than 59 months old | |
| RU2362997C2 (ru) | Способ выявления нарушения функции фагоцитов при развитии рецидивирующих инфекционных процессов | |
| RU2430364C1 (ru) | Способ прогнозирования характера прогрессирующего течения хронической болезни почек | |
| RU2782491C1 (ru) | Способ превентивной оценки риска снижения уровня здоровья юношей подросткового возраста | |
| RU2549435C1 (ru) | Способ донозологической диагностики нарушений здоровья от воздействия локальной вибрации | |
| Ceylan et al. | Examining the Effect of Venipuncture Technique with Vacutainer and Injector on the Rate of Hemolysis | |
| Sohn | Education and self-awareness of health: Toward a better understanding of self-rated health | |
| RU2552297C1 (ru) | Способ определения степени тяжести бронхиальной астмы |